Results 11 to 20 of about 5,080,573 (227)

Mantle Cell Lymphoma Presenting with Acute Bilateral Ophthalmoplegia [PDF]

open access: yesTürk Oftalmoloji Dergisi, 2017
A 72-year-old woman presented with acute onset of double vision, bilateral complete blepharoptosis, and nearly complete ophthalmoplegia. Orbital and brain magnetic resonance imaging were normal.
Yaran Koban   +6 more
doaj   +2 more sources

Mantle cell lymphoma

open access: yesHaematologica, 2009
This perspective article by Drs. Pileri and Falini examines the diagnosis and bio-pathology of mantle cell lymphoma in the light of the criteria of the WHO Classification and recent reports. See related articles on pages 1555, 1563 and 1595.
Stefano A. Pileri, Brunangelo Falini
doaj   +3 more sources

“Double trouble” – synchronous mantle cell lymphoma and metastatic squamous cell carcinoma in an inguinal lymph node

open access: yesPolish Journal of Pathology, 2017
Multiple primary neoplasms may also occur synchronously. Lymphoma may coexist with second malignant tumor in its primary location or malignant tumor may metastases to lymphomatous lymph nodes.
Anna Szumera-Ciećkiewicz   +2 more
doaj   +2 more sources

Case Report: Occult mantle cell lymphoma in a synchronous rectal collision tumor with adenocarcinoma: retrospective reclassification and multispecimen molecular profiling. [PDF]

open access: yesFront Oncol
Collision tumors composed of colorectal adenocarcinoma and mantle cell lymphoma are exceptionally rare, and component-resolved molecular characterization is largely lacking. We report a 65-year-old woman who initially presented with rectal adenocarcinoma
Zhang Q, Xiu Y, Li J, Cao X.
europepmc   +2 more sources

Primary gastric mantle cell lymphoma [PDF]

open access: yesHematology Reports, 2012
Mantle cell lymphoma represents 2,5-7% all of non Hodgkin’s lymphomas. Stomach is the most common site of extranodal lymphoma. However, that is not the case with mantle cell lymphoma, which is extremely rare.
Duska Petranovic   +7 more
doaj   +5 more sources

Indolent mantle cell lymphoma

open access: yesHaematologica, 2011
Mantle cell lymphoma (MCL) accounts for approximately 6% of all non-Hodgkin’s lymphomas[1][1] and is characterized by the over-expression of cyclin D1 with cell cycle dysregulation, secondary to the genetic abnormality t(11;14)(q13;q32).[2][2] It often has an aggressive clinical course and ...
Michelle Furtado, Simon Rule
doaj   +3 more sources

Smoldering mantle cell lymphoma [PDF]

open access: yesJournal of Experimental & Clinical Cancer Research, 2017
Background Mantle cell lymphoma (MCL) is an aggressive disease, with poor prognosis and a limited survival. However, some patients with indolent MCL can survive beyond 7~10 years. These patients remain largely asymptomatic and can be in observation for a
Haige Ye   +6 more
doaj   +3 more sources

Factores pronósticos biológicos y clínicos en el linfoma de células del manto [PDF]

open access: yes, 2008
[spa] El linfoma de células del manto (LCM) es una entidad heterogénea tanto en sus aspectos biológicos como en su comportamiento clínico. La existencia de pacientes con mala respuesta al tratamiento sugiere que, de manera análoga a otros síndromes ...
Ferrer del Álamo, Ana
core   +6 more sources

Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma

open access: yesPathology and Oncology Research, 2023
Composite mantle cell lymphoma and classical Hodgkin lymphoma is very rare and the actual origin of it is still unclear. Here we reported a new case of composite mantle cell lymphoma and classical Hodgkin lymphoma and analyzed its molecular changes ...
Hongyu Wang   +4 more
doaj   +1 more source

Impact of Pre-transplant Induction Therapy on Outcomes of Patients Who Undergo Autologous Stem Cell Transplantation for Mantle Cell Lymphoma in First Complete Remission ☆

open access: yesHematology/Oncology and Stem Cell Therapy, 2023
Mantle cell lymphoma is a rare subtype of non-Hodgkin’s lymphoma with poor prognosis and continue to be challenging to treat. The choice of first line induction regimen remains a topic of debate due paucity of clinical trials.
Omar Albanyan   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy